Forschergruppe Diabetese e. V., Ingolstaedter Landstraße 1, Neuherberg, 85764, Munich, Germany.
Sant Marti de Provençals Primary Care Centres, Barcelona, Spain.
Cardiovasc Diabetol. 2020 Apr 17;19(1):47. doi: 10.1186/s12933-020-01022-7.
The 5th Cardiovascular Outcome Trial (CVOT) Summit was held in Munich on October 24th-25th, 2019. As in previous years, this summit served as a reference meeting for in-depth discussions on the topic of recently completed and presented CVOTs. This year, focus was placed on the CVOTs CAROLINA, CREDENCE, DAPA-HF, REWIND, and PIONEER-6. Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussions evolved from CVOTs to additional therapy options for heart failure (ARNI), knowledge gained for the treatment and prevention of heart failure and diabetic kidney disease in populations with and without diabetes, particularly using SGLT-2 inhibitors and GLP-1 receptor agonists. Furthermore, the ever increasing impact of CVOTs and substances tested for primary prevention and primary care was discussed. The 6th Cardiovascular Outcome Trial Summit will be held in Munich on October 29th-30th, 2020 (https://www.cvot.org).
第五届心血管结局试验（CVOT）峰会于 2019 年 10 月 24 日至 25 日在慕尼黑举行。与往年一样，此次峰会是一次参考会议，旨在深入讨论最近完成并发表的 CVOT 相关内容。今年的重点是 CAROLINA、CREDENCE、DAPA-HF、REWIND 和 PIONEER-6 这几项 CVOT。会议为糖尿病专家、心脏病专家、内分泌学家、肾病学家和全科医生重点介绍了 CVOT 对糖尿病管理的影响以及对新治疗方案的影响。讨论从 CVOT 扩展到心力衰竭（ARNI）的其他治疗选择，涵盖了人群中针对心力衰竭和糖尿病肾病的治疗和预防的知识，特别是使用 SGLT-2 抑制剂和 GLP-1 受体激动剂。此外，还讨论了 CVOT 和用于一级预防和初级保健的物质的影响日益增加。第六届心血管结局试验峰会将于 2020 年 10 月 29 日至 30 日在慕尼黑举行（https://www.cvot.org）。
